Axon Enterprise, Inc (NASDAQ:AXON) Shares Acquired by Sigma Planning Corp

Sigma Planning Corp grew its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 50.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 2,472 shares of the biotechnology company's stock after acquiring an additional 827 shares during the quarter. Sigma Planning Corp's holdings in Axon Enterprise were worth $1,300,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Fourth Dimension Wealth LLC bought a new stake in Axon Enterprise in the fourth quarter worth $30,000. Bartlett & CO. Wealth Management LLC lifted its position in Axon Enterprise by 132.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after buying an additional 33 shares during the last quarter. Catalyst Capital Advisors LLC bought a new stake in Axon Enterprise in the first quarter worth $32,000. Alpine Bank Wealth Management bought a new stake in Axon Enterprise in the first quarter worth $40,000. Finally, Elequin Capital LP bought a new stake in Axon Enterprise in the fourth quarter worth $46,000. 79.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on the company. The Goldman Sachs Group increased their target price on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Bank of America increased their target price on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. Barclays increased their target price on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Needham & Company LLC increased their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Finally, UBS Group assumed coverage on Axon Enterprise in a research note on Wednesday. They issued a "neutral" rating and a $820.00 target price on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, Axon Enterprise has a consensus rating of "Moderate Buy" and a consensus target price of $763.75.

Axon Enterprise Trading Up 1.4%

AXON traded up $10.23 during trading hours on Friday, reaching $756.09. The company's stock had a trading volume of 404,179 shares, compared to its average volume of 602,176. Axon Enterprise, Inc has a fifty-two week low of $279.02 and a fifty-two week high of $830.21. The stock has a market cap of $58.86 billion, a PE ratio of 182.63, a P/E/G ratio of 87.03 and a beta of 1.29. The business's 50-day moving average is $763.54 and its 200-day moving average is $645.97. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The firm had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. During the same period in the prior year, the firm posted $1.15 earnings per share. The firm's quarterly revenue was up 31.3% on a year-over-year basis. As a group, equities research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Michael Garnreiter sold 5,913 shares of the company's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the transaction, the director directly owned 17,740 shares in the company, valued at $13,482,400. This represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Joshua Isner sold 9,905 shares of the company's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $738.03, for a total value of $7,310,187.15. Following the transaction, the president owned 298,809 shares in the company, valued at $220,530,006.27. This trade represents a 3.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,642 shares of company stock valued at $30,500,428 over the last ninety days. 4.40% of the stock is owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.